Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The response includes several label-supported safety/administration concepts (indication, ER dosing/food consistency, not chewed/crushed, contraindication, and adverse effects tied to serum concentrations). However, it contains multiple mechanistic statements that are either incorrect or not supported by the provided label text (e.g., theophylline as a non-selective PDE inhibitor and adenosine antagonism as a contributor to bronchodilation), and it omits key label warnings/precautions content and specific monitoring/overdose-related guidance.
Category Scores
Accurate Statements
Theophylline is indicated for the treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema and chronic bronchitis).
INDICATIONS AND USAGE: "indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis."
Theophylline (anhydrous) extended-release tablets 400 mg or 600 mg are taken once a day in the morning or evening.
DOSAGE AND ADMINISTRATION: "extended-release tablets 400 mg or 600 mg can be taken once a day in the morning or evening."
Theophylline (anhydrous) extended-release tablets should be taken with meals if the patient chooses with food, and dosing should be consistent with or without food.
DOSAGE AND ADMINISTRATION: "recommended ... be taken with meals" and "product whenever dosed be dosed consistently with or without food."
Theophylline (anhydrous) extended-release tablets are not to be chewed or crushed because it may lead to rapid release with potential for toxicity.
DOSAGE AND ADMINISTRATION: "are not to be chewed or crushed because it may lead to a rapid release of theophylline with the potential for toxicity."
Theophylline extended-release tablets are contraindicated in patients with a history of hypersensitivity to theophylline or other components.
CONTRAINDICATIONS: "contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product."
Adverse reactions are generally mild when peak serum theophylline concentrations are < 20 mcg/mL and include transient caffeine-like effects such as nausea, vomiting, headache, and insomnia.
ADVERSE REACTIONS: "generally mild when peak serum theophylline concentrations are < 20 mcg/mL ... transient caffeine-like ... nausea, vomiting, headache and insomnia."
More serious adverse reactions can occur when peak serum theophylline concentrations exceed 20 mcg/mL, including persistent vomiting, cardiac arrhythmias, and intractable seizures.
ADVERSE REACTIONS: "When peak serum theophylline concentrations exceed 20 mcg/mL ... including persistent vomiting, cardiac arrhythmias, and intractable seizures which can be lethal."
Unsupported Statements
Theophylline works by relaxing the muscles around the airways in the lungs, helping to open them up and make breathing easier.
Not explicitly stated in the provided label sections as phrased; label states "smooth muscle relaxation (i.e., bronchodilation)" but the response does not cite/align with that exact label wording and also makes a broad benefit phrasing not directly supported by the supplied text.
Theophylline is typically taken in oral form.
The provided label excerpts specifically describe extended-release tablets and dosing instructions, but do not explicitly state "typically taken in oral form" in the supplied text.
Theophylline belongs to a class of drugs called bronchodilators.
The label describes smooth muscle relaxation/bronchodilation as an action, but the excerpt does not explicitly label it as belonging to a drug class named "bronchodilators."
Theophylline acts as a non-selective phosphodiesterase inhibitor.
Label excerpt says bronchodilatation is "mediated by the inhibition of two isozymes of phosphodiesterase (PDE III and, to a lesser extent, PDE IV)" and also notes other mechanisms not involving PDE III or adenosine antagonism for non-bronchodilator prophylactic effects. The term "non-selective" and broad claim are not supported by the provided text.
Theophylline antagonizes adenosine receptors.
The label excerpt mentions adenosine receptor antagonism in mechanisms of adverse effects and in the discussion of non-bronchodilator prophylactic actions as not involving adenosine receptor antagonism. It does not explicitly support that the drug "antagonizes adenosine receptors" as a general mechanistic action for the drug overall in the provided text.
By inhibiting phosphodiesterase, theophylline increases intracellular cyclic adenosine monophosphate (cAMP) levels.
No cAMP increase statement is present in the provided label excerpts.
Increased cAMP levels lead to relaxation of airway smooth muscle.
No cAMP-to-smooth-muscle relaxation causal link is stated in the provided label excerpts.
Antagonism of adenosine receptors contributes to bronchodilation.
Label states non-bronchodilator prophylactic actions "do not involve inhibition of PDE III or antagonism of adenosine receptors." The provided text does not support adenosine antagonism contributing to bronchodilation.
Antagonism of adenosine receptors may have anti-inflammatory effects.
No anti-inflammatory effect claim is supported by the provided label excerpts.
Common side effects of theophylline can include nausea, vomiting, headache, insomnia, and irritability.
Label explicitly lists nausea, vomiting, headache, insomnia as transient caffeine-like adverse effects when peak levels are < 20 mcg/mL, but does not describe "irritability" as part of the common side effects set in that same categorization.
More serious side effects ... include irregular heart rhythms.
Label describes "cardiac arrhythmias" at peak > 20 mcg/mL but does not specifically use the phrase "irregular heart rhythms."
Serious side effects ... can include significant gastrointestinal distress.
Label provides specific GI manifestations (e.g., persistent vomiting) and abdominal pain elsewhere, but does not use the phrase "significant gastrointestinal distress."
There are alternative treatments for asthma and COPD, including inhaled corticosteroids, long-acting beta-agonists, and short-acting bronchodilators.
Not addressed in the provided label excerpts.
The choice of treatment for asthma or COPD depends on the individual patient's condition, severity, and response to medication.
Not addressed in the provided label excerpts.
The exact price of theophylline can vary depending on the pharmacy, dosage, and insurance coverage.
Not addressed in the provided label excerpts.
Because theophylline has expired patents and is available in generic formulations, it generally makes it more affordable than newer, branded drugs.
Not addressed in the provided label excerpts.
Contradictions
Low
AI Statement
Theophylline acts as a non-selective phosphodiesterase inhibitor.
Label Reference
CLINICAL PHARMACOLOGY (Mechanism of Action): "bronchodilatation is mediated by the inhibition of two isozymes of phosphodiesterase (PDE III and, to a lesser extent, PDE IV)" (implies selective to those isozymes rather than non-selective as claimed).
Low
AI Statement
Antagonism of adenosine receptors contributes to bronchodilation.
Label Reference
CLINICAL PHARMACOLOGY (Mechanism of Action): non-bronchodilator prophylactic actions "probably mediated ... do not involve inhibition of PDE III or antagonism of adenosine receptors." (The claim ties adenosine antagonism to bronchodilation, which is not supported by provided text.)
Important Omissions
Warnings and precautions content is not evaluated because the prompt does not include the label "WARNINGS" section text, but the AI response also does not mention label-specific guidance linked to serious toxicity (e.g., the presence of an OVERDOSAGE reference and detailed toxicity manifestations).
Importance:
Moderate
Drug interaction specifics from the label (examples of inhibitors/inducers and the interaction concept) are omitted: adding inhibitors of theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping drugs that enhance metabolism (e.g., carbamazepine, rifampin).
Importance:
Moderate
Administration instructions about transfer from immediate-release/other products, peak/trough variability with once-daily dosing, and guidance on intact matrix tablet passage in stool/colostomy are omitted.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Mechanism-of-action inaccuracies and omission of specific drug-interaction guidance could lead to incomplete or misleading label-aligned counseling. Safety-related label content (serious adverse reactions at high serum concentrations, contraindication, and key administration warnings for ER tablets) is partially reflected.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple mechanistic statements are not supported or conflict with the provided label excerpt (e.g., "non-selective PDE inhibitor" and adenosine antagonism contributing to bronchodilation), and key interaction/administration details are omitted.
Suggested Improvement
Restrict mechanism claims to the provided label text (PDE III/PDE IV inhibition; avoid unsupported cAMP and "non-selective" language; do not state adenosine antagonism contributes to bronchodilation). Add label-supported drug interaction warnings (examples of metabolism inhibitors/inducers) and include ER administration details (food consistency, no chewing/crushing, potential intact matrix passage, transfer guidance, and variability of peak/trough levels).